Duloxetine has been increasingly administered, but the associated cardiovascular adverse event risk is not clearly understood. Therefore, we identified the association between duloxetine and cardiovascular adverse events through an analysis of heart rate and blood pressure change. We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and psycINFO in June 2019. The title, abstract, and full text were checked in order to obtain articles. A meta-analysis was conducted with random effect model and quality of articles was evaluated using Cochrane Risk of Bias 2.0. The manuscript has been written according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) harm checklist. A total of 4,009 studies were screened by the title and abstract. After reviewing 186 full texts, 17 studies were finally selected for the meta-analysis. Nine of the 17 studied duloxetine given for mood disorders and 8 for pain control. The duration of 14 studies was under 13 weeks. Cardiovascular adverse events (hypertension, myocardial infarction, transient ischemic attack, tachycardia atrial fibrillation, and cerebrovascular accident) were reported. The meta-analysis demonstrated that duloxetine increased heart rate by 2.22 beats/min (95% confidence intervals [CIs]: 1.53, 2.91) and diastolic blood pressure by 0.82 mmHg (95% CI: 0.17, 1.47). Our findings may be the signal for the safety of cardiovascular disease for short-term use of duloxetine. Well-designed pharmaco-epidemiological studies evaluating the causal relationship between long-term use of duloxetine and cardiovascular disease is still necessary.

度洛西汀已被越来越多地给药，但是尚不清楚相关的心血管不良事件风险。因此，我们通过分析心率和血压变化确定了度洛西汀与心血管不良事件之间的关联。我们于2019年6月搜索了PubMed，EMBASE，Cochrane对照试验中央注册系统，ClinicalTrials.gov和psycINFO。检查了标题，摘要和全文，以便获得文章。使用随机效应模型进行荟萃分析，并使用Cochrane Bias 2.0风险评估文章的质量。该手稿是根据PRISMA（系统评价和Meta分析的首选报告项目）危害清单编写的。标题和摘要共筛选了4,009篇研究。在审查了186篇全文之后，最终选择了17项研究进行荟萃分析。在17个研究的度洛西汀中，有9个用于情绪障碍，8个用于疼痛控制。14项研究的持续时间不到13周。据报道有心血管不良事件（高血压，心肌梗塞，短暂性脑缺血发作，心动过速，心脑血管意外）。荟萃分析表明，度洛西汀可将心率提高2.22次/分钟（95％置信区间[CIs]：1.53，2.91），舒张压升高0.82 mmHg（95％CI：0.17，1.47）。我们的发现可能是短期使用度洛西汀对心血管疾病安全性的信号。评估长期使用度洛西汀与心血管疾病之间因果关系的设计良好的药物-流行病学研究仍然是必要的。